Author

Hal J. Burstein

Observed name: Hal Burstein

Institution: Dana-Farber Cancer Institute

Observed institution: Dana-Farber Cancer Institute

OpenAlex ID: A5024427583

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

2021 · Michael Gnant, Amylou C. Dueck, et al. · Journal of Clinical Oncology · 235

Abstract GS1-07: Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial

2022 · Michael Gnant, Amylou C Dueck, et al. · Cancer Research · 1

Correction: Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer

2026 · Eileen Shinn, David Zahrieh, et al. · Breast Cancer Research and Treatment

Abstract P4-12-01: Adherence with adjuvant endocrine therapy with or without Palbociclib in the PALLAS trial

2022 · Eileen Shinn, David Zahrieh, et al. · Cancer Research

Works count: 4

Citation count: 236

H-index: 1

I10-index: 1